Key Milestone | Completion of the first patient enrolled in the phase I study of the PDC SC-102

On Dec 20, 2024, Conjustar announced that the first patient has been enrolled in the Phase I clinical trial of SC-102, the first novel PDC targeting EphA2 in China. The trial is being conducted at the Fudan University Shanghai Cancer Center. The PI of this trial are Professor Hongxia Wang and Professor Jian Zhang.
This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of SC-102 in patients with advanced tumors positive for EphA2. The enrollment and dosing of the first patient marks an key milestone in Conjustar’s R&D of PDCs for anti-cancer therapy.

About SC-102

SC-102 is an novel EphA2-targeted PDC molecule, composed of a targeting peptide and  linked a payload via a linker. EphA2（Ephrin receptor A2） belongs to the receptor tyrosine kinase (RTK) family, which includes 14 Eph receptors and 8 ephrin ligands.EphA2 is overexpressed on the surface of cancer cells in pancreatic, lung, colon, ovarian and other cancers.